Roche has opened its pocket book again to reach a deal with Belgium's ReMynd. ReMynd has novel therapies in development to inhibit a-synuclein in Parkinson's and tau neurotoxicity in Alzheimer's. Obviously, these are two sexy, high-value areas that have proven to be very difficult to crack up until now by a myriad of companies.
Roche will pay ReMynd up to $637 M in milestone payments should its programs prove to be successful in the clinic. ReMynd has six programs aimed at either Parkinson's or Alzheimer's in its pipeline, and two more aimed at diabetes. See Fierce Biotech.
Posted by Bruce Lehr September 7th 2010.